What changed for Kidney Cancer
A plain English summary of what recently moved in the public data Voxsanity tracks for Kidney Cancer. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting worldwide 316 to 323 (+7)
- Trials on record 1,914 to 1,929 (+15)
Newly subsidised on the PBS
No medicines were newly subsidised on the PBS for Kidney Cancer in July 2026. Voxsanity tracks 8 PBS-subsidised medicines for this condition; none of them was listed for the first time this month.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 105 trials tracked for Kidney Cancer that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT03294083 · results posted 18 June 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT03294083) enrolled 95 people in total across six groups. The early phase (Part 1) tested two different doses of a treatment called Pexa-Vec given by intravenous drip (into a vein), with 3 people in each dose group. The larger phase (Part 2) tested four different treatment approaches across four arms: Pexa-Vec injected directly into tumours combined with another drug called cemiplimab (15 people); cemiplimab alone (16 people); Pexa-Vec by drip combined with cemiplimab at one dose level (30 people); and Pexa-Vec by drip comb...
-
NCT04941768 · results posted 28 November 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 105 participants, all of whom received a combination of two medicines — avelumab and axitinib — for advanced kidney cancer (renal cell carcinoma). All 105 participants were recorded as having completed the study. The trial was primarily measuring how many participants were still alive 12 months after starting treatment, and it also tracked a range of secondary measures including survival at 24 months, how long participants lived overall, how many participants' tumours shrank or disappeared, how many had their disease...
-
NCT04320888 · results posted 6 November 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04320888) enrolled just one paediatric (child or adolescent) participant who received a medicine called selpercatinib. The trial was designed to measure how many participants showed a measurable reduction in their tumour (known as an "objective response"), how long they went without their disease getting worse (called "progression-free survival"), and what proportion experienced serious side effects (graded 3 or 4 out of 5 in severity, meaning significant or severe). The reported data shows that 100% of participants — tha...
-
NCT03937219 · results posted 10 September 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03937219) enrolled 855 people in total — 428 in a group receiving cabozantinib combined with two immunotherapy medicines (nivolumab and ipilimumab), and 427 in a group receiving a placebo combined with the same two immunotherapy medicines. The trial was measuring two main things: how long participants went without their disease getting worse (called progression-free survival), and how long participants lived overall (called overall survival). The reported data shows that for progression-free survival — the time from when...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04508725 · results posted 25 July 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04508725) enrolled a total of 19 people across three groups. Twelve participants were in Arm 1, which received a combination of two types of targeted cancer medicines (a tyrosine kinase inhibitor and an immune checkpoint inhibitor — drugs that work on different parts of cancer cell growth and the immune system). Five participants were in Arm 2, which received a different treatment not involving an immune checkpoint inhibitor. Two participants were in Arm 3, meaning they took part in both arms one after the other. The trial...
-
NCT02711202 · results posted 4 June 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 20 kidney transplant recipients in total — 7 people received sirolimus and 13 received tacrolimus. Both are medicines used after a transplant to stop the body rejecting the new kidney. The trial was measuring whether patients stayed alive, whether their transplanted kidney continued to work, and how well that kidney was functioning at one year after the transplant. The reported data shows that all 7 patients in the sirolimus group and all 13 in the tacrolimus group were recorded as alive at the end of the study. Six...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03138512 · results posted 18 December 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03138512) looked at treatments for kidney cancer (renal cell carcinoma) after surgery. It was split into two parts. In Part A, around 404 people received a combination of two medicines called nivolumab and ipilimumab, and about 407 people received a placebo (an inactive treatment). In Part B, roughly 204 people received the combination, 208 received a placebo, and 411 received nivolumab on its own. In total, over 1,600 people took part across the two parts. The trial was mainly measuring how long people went without their...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01693822 · results posted 21 November 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 65 people, all of whom were in a single group receiving a medicine called axitinib. All 65 participants completed the study. The trial was primarily looking at how many people were still alive and had not seen their cancer grow or spread by the six-month mark. It also tracked a number of secondary measures, including how tumours responded to treatment, how long it took for the cancer to progress, how long participants lived overall, side effects experienced, and how many people became suitable for surgery to remove th...
-
NCT02684006 · results posted 29 October 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 886 people with kidney cancer — 442 received a combination of two medicines called avelumab and axitinib, and 444 received a medicine called sunitinib. The trial was measuring how long participants went without their disease getting worse (called progression-free survival), how long participants lived overall (overall survival), and what proportion of participants saw their tumours shrink or disappear (objective response). Some results were reported specifically for participants whose tumours tested positive for a pro...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03849118 · results posted 17 May 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 300 participants, all of whom received an investigational imaging agent called 89Zr-girentuximab (also referred to as 89Zr-TLX250). Of those, 275 completed the trial and 25 did not complete it. The trial was measuring how well a specialised type of scan — called a PET/CT scan — could identify a specific type of kidney tumour known as clear cell renal cell carcinoma (ccRCC) in people who had an uncertain or "indeterminate" mass on their kidney. The scan results were then compared against tissue analysis (histology), wh...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04148937 · results posted 5 April 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04148937) enrolled 52 people in total across eight groups. Participants were divided into two broad cohorts: Cohort A received the investigational drug LY3475070 on its own at different doses and schedules, and Cohort B received LY3475070 combined with another drug called pembrolizumab, again at different doses and schedules. The trial was primarily measuring how many participants experienced what are called "dose-limiting toxicities" (DLTs) — that is, serious unwanted reactions considered severe enough to be linked to the...
-
NCT04489771 · results posted 28 February 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04489771) enrolled 154 adults in total — 78 who received a 200 mg dose of a medicine called belzutifan, and 76 who received a 120 mg dose. The trial was measuring how the tumours in these participants responded to treatment, using a standard set of imaging-based rules called RECIST 1.1. A review panel that did not know which dose each participant received (called a "blinded independent central review") assessed the scans. No participants were recorded as having formally "completed" the study by the time data was submitted,...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04338269 · results posted 28 February 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04338269) enrolled 522 people in total — 259 in the cabozantinib-only group and 263 in the group receiving atezolizumab plus cabozantinib combined. The trial was measuring two main things: how long participants went without their cancer growing or spreading (called progression-free survival), and how long participants lived overall (called overall survival). It also looked at secondary measures including what proportion of participants saw their tumours shrink (response rate) and how long those responses lasted. The repor...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04021238 · results posted 13 November 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT04021238) enrolled 24 participants, all of whom completed the study with no drop-outs. The trial involved a single group of people who received an ultrasound contrast agent called Perflutren Lipid Microsphere (a substance injected into the body to make ultrasound images clearer). The goal was to measure specific image-based characteristics of kidney masses — that is, growths or lumps found on the kidney — using a specialised type of ultrasound called contrast-enhanced ultrasound (CEUS). The researchers were trying to build...
-
NCT03824808 · results posted 25 October 2023
According to the results reported on ClinicalTrials.gov, this trial enrolled 21 people in total — 11 in the Treatment Group and 10 in the Control Group. All 21 participants completed the study with no dropouts. The trial was measuring post-operative pain and a range of other recovery-related outcomes after surgery, including how much pain relief medication people needed, how long they stayed in hospital, and how quickly their digestive system returned to normal. The reported data shows that for the main outcome — pain scores rated on a scale of 0 (no pain) to 10 (worst pain ever) — both group...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02855203 · results posted 3 August 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT02855203) enrolled 30 participants, all of whom completed the study. Every participant received the same combination treatment: SABR (a precise, high-dose form of radiation therapy) together with a drug called pembrolizumab (an immunotherapy medicine). The trial was looking at side effects from the treatment, as well as several measures related to how participants' cancer responded and progressed over time. The reported data shows that 4 out of 30 participants experienced what are described as "Grade 3 treatment-related a...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03024996 · results posted 3 August 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT03024996) enrolled 778 people who had been treated for kidney cancer (renal cell carcinoma) and were at risk of it returning. Participants were randomly assigned to receive either atezolizumab (390 people) or a placebo — an inactive lookalike treatment (388 people). The trial's main goal was to measure "disease-free survival," which means how long participants went without their cancer coming back or dying from any cause. The reported data shows that, for the primary outcome of investigator-assessed disease-free survival,...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03729245 · results posted 11 April 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT03729245) enrolled 623 people with previously untreated advanced kidney cancer (renal cell carcinoma). Participants were split into two groups: 311 people received a combination of two medicines called bempegaldesleukin and nivolumab, while 312 people received one of two standard medicines, sunitinib or cabozantinib. The trial was measuring how many people's tumours shrank or disappeared (called the objective response rate), how long people lived overall, and how long people went without their disease getting worse. The r...
-
NCT03428217 · results posted 20 March 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT03428217) enrolled 444 people in total — 223 in one group (called "Pbo-Cabo") and 221 in the other (called "CB-Cabo"). Both groups went on to receive a drug called cabozantinib; the difference between the groups was what they received beforehand. The trial was primarily measuring how long participants went without their disease getting worse (called "progression-free survival"), as judged by an independent panel of radiology experts reviewing scans. It also measured how long participants lived overall, and how long they we...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03149003 · results posted 30 January 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT03149003) enrolled people with a type of brain tumour called glioblastoma (GBM) that had come back or continued to grow after initial treatment. A total of 221 participants took part across two phases. A small first phase (4 people) tested a combination of an investigational treatment called DSP-7888 Dosing Emulsion together with a medicine called bevacizumab, mainly to look at serious side effects. The larger second phase (217 people) then compared that combination against bevacizumab on its own, with participants split r...
-
NCT02996110 · results posted 19 December 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT02996110) tested five different two-drug combinations in people with cancer. All combinations included nivolumab paired with one of four other medicines: ipilimumab, relatlimab, BMS-986205, or BMS-813160 (at either a 150 mg or 300 mg dose). The trial had two tracks, and some participants moved between tracks or were re-assigned to a different combination during the study. In total, across all five groups, roughly 182 people entered the pre-treatment phase, with between 17 and 65 participants starting in each group. The re...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02432846 · results posted 22 August 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT02432846) enrolled 88 people in total with kidney cancer — 58 received a combination of an investigational treatment called ilixadencel (also known as Intuvax) plus surgery (nephrectomy) and a standard medicine called sunitinib, while 30 received surgery and sunitinib alone. Participants were divided into two groups based on their level of disease risk: high-risk (25 people total) and intermediate-risk (63 people total). The trial's main goal was to measure how long participants lived overall, and what percentage were stil...
-
NCT03141177 · results posted 26 April 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT03141177) enrolled a total of 701 participants across three groups — Treatment A (323 people), Treatment B (50 people), and Treatment C (328 people). The trial was primarily measuring **progression-free survival (PFS)** — that is, how long participants went without their condition getting worse or without dying. It also tracked several secondary measures, including overall survival (how long participants lived), the proportion of participants whose tumours shrank or disappeared (called objective response rate), and the num...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00126672 · results posted 25 April 2022
According to the results reported on ClinicalTrials.gov, this trial enrolled 36 people, all of whom received a medicine called Rapamycin (also known as sirolimus). Of those 36, 28 completed the study and 8 did not finish. The trial was looking at how the drug affected certain tumours and other growths related to a genetic condition called Tuberous Sclerosis Complex (TSC) — a condition that can cause non-cancerous growths to form in many parts of the body. The reported data shows that the main thing being measured was the "objective response rate" — meaning the proportion of participants whose...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04033991 · results posted 18 February 2022
According to the results reported on ClinicalTrials.gov, this study enrolled 684 people with advanced or metastatic kidney cancer (cancer that had spread beyond the kidney). It was an observational study — meaning researchers reviewed real-world medical records rather than assigning people to specific treatments — tracking patients who had received the drug sunitinib as their first treatment, axitinib as a second treatment, or both in sequence. In total, 622 participants received first-line sunitinib, and 121 received second-line axitinib; 59 of those had taken sunitinib first and then axitini...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00003102 · results posted 5 January 2022
According to the results reported on ClinicalTrials.gov, this trial enrolled 15 people in total across three groups, each receiving a different dose of radiation delivered via a radioactive antibody treatment. There were 3 participants in the lowest-dose group (50 cGy), 9 in the middle-dose group (75 cGy), and 3 in the highest-dose group (100 cGy). The trial was primarily measuring side effects — specifically how many participants experienced any unwanted health events, and how many experienced what are called "dose-limiting toxicities" (serious side effects severe enough to prevent further do...
-
NCT03142334 · results posted 28 December 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT03142334) enrolled 994 people with kidney cancer — 496 assigned to receive pembrolizumab (an immunotherapy medicine) and 498 assigned to receive a placebo (an inactive treatment). The trial was designed to measure how long participants stayed free of their cancer returning or spreading after surgery, and to track overall survival, as well as a number of other outcomes related to disease recurrence and side effects. The reported data shows that for the primary outcome — disease-free survival, meaning the length of time bef...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02811861 · results posted 24 September 2021
According to the results reported on ClinicalTrials.gov, this trial enrolled 1,069 people across three groups — 357 in each group — who were assigned to one of three treatment combinations: lenvatinib plus everolimus, lenvatinib plus pembrolizumab, or sunitinib alone (which served as the comparison group). The trial was primarily measuring how long participants went without their disease getting worse or dying — a period called "progression-free survival." Several other outcomes, including overall survival, response rates, and side-effect data, were also planned but had not yet been reported a...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00070070 · results posted 8 July 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT00070070) enrolled a total of 6 participants across four groups, called Cohorts 1 through 4. Cohort 1 had 1 participant, Cohorts 2 and 3 had no participants enrolled, and Cohort 4 had 5 participants. All 6 participants who started the trial completed it. The trial was measuring whether certain side effects called "dose-limiting toxicities" occurred — that is, serious enough reactions that would require a participant to stop treatment — and also tracking changes in the immune system, such as the development of specific anti...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03494816 · results posted 30 June 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT03494816) enrolled 24 participants in a single group — meaning everyone received the same treatment with no comparison group. The trial was measuring whether a treatment could shrink a blood-clot-like tumour growth (called a venous tumour thrombus) that had extended from a kidney tumour into a large vein. Specifically, it tracked whether the level of this growth — rated on a scale called the Mayo Classification, where higher levels mean the growth has extended further into the body — was lower after 9 weeks of treatment co...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
See all 105 reported results for Kidney Cancer
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, kidney cancer currently attracts a very large amount of public research investment from the United States, and that level of support has remained broadly steady over recent years. This consistency suggests that kidney cancer is an established priority within the global research community, and that scientists are continuing to pursue questions about how to better unde...
See the full Kidney Cancer page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.